Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Deleting

No Items In Cart
We apologize your item could not be found. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
No Items In Cart
Latest Blogs
There is increasing demand for advanced manufacturing technologies for fill-finish operations of parenteral drug products. To meet manufacturing requirements for multiple container and component types, flexible fill-finish equipment is at the forefront of most pharmaceutical, biotech, and CDMOs’ fill-finish strategy. Flexible fill-finish technology is suitable for variable batch sizes allowing for scaling from clinical to commercial in multiple drug delivery presentations. With the ability to launch in vial configurations, prefilled syringes, or other combination products including devices, flexible fillers are beneficial to drug developers who are looking for lifecycle management of their drug products.
Latest Blogs
My greatest achievement is founding West without Borders*
I’ve worked at West for 21 years! One of my friends approached me and said he would love it if I joined West. He kept telling me what a great company West was and eventually I agreed. I loved the job in the sales department because I got to work with a lot of bold personalities. I’m very outgoing and talkative and so are account managers.
Latest Blogs
The concept of Extractables and Leachables (E&L) is well known today, especially since the publication of United States Pharmacopeia (USP) monographs <1663>1 and <1664>2. USP <1663> defined extractables as “organic and inorganic chemical entities that are released from a pharmaceutical packaging/delivery system and into an extraction solvent under laboratory conditions.” Leachables are defined in USP <1664> as “foreign organic and inorganic chemical entities that are present in a packaged drug product because they have migrated into the packaged drug product from a packaging/delivery system, packaging component or packaging material of construction under normal conditions of storage and use or during drug product stability studies.”
Latest Blogs
Today I am a Senior Vice President at Novo Nordisk one of West’s biggest customers.
A few years ago, I used to work quite closely with the West team. I clearly remember my first negotiations with West. Our interactions gave me the feeling that your team members had a deep understanding of our patients, the urgency of the particular matter we were negotiating about. I was under no mistake that their attitude and behavior towards my organization demonstrated a thorough wish to continue working together for many years to come.